Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Leases (2019 - 2025)

Vanda Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 39.5% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, down 39.5%, while the annual FY2025 figure was $3.0 million, 39.5% down from the prior year.
  • Operating Leases for Q4 2025 was $3.0 million at Vanda Pharmaceuticals, down from $3.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $12.4 million in Q4 2021 and bottomed at $3.0 million in Q4 2025.
  • The 5-year median for Operating Leases is $7.7 million (2023), against an average of $7.5 million.
  • The largest annual shift saw Operating Leases decreased 8.35% in 2021 before it tumbled 39.5% in 2025.
  • A 5-year view of Operating Leases shows it stood at $12.4 million in 2021, then decreased by 28.73% to $8.8 million in 2022, then fell by 20.5% to $7.0 million in 2023, then decreased by 29.43% to $4.9 million in 2024, then tumbled by 39.5% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Operating Leases are $3.0 million (Q4 2025), $3.4 million (Q3 2025), and $3.9 million (Q2 2025).